Blue Owl Capital Holdings LP Sells 30,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Blue Owl Capital Holdings LP cut its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 17.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 139,450 shares of the company’s stock after selling 30,000 shares during the period. Centessa Pharmaceuticals comprises 0.3% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 28th biggest holding. Blue Owl Capital Holdings LP’s holdings in Centessa Pharmaceuticals were worth $3,488,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. TD Waterhouse Canada Inc. bought a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares in the last quarter. DNB Asset Management AS bought a new position in shares of Centessa Pharmaceuticals during the third quarter worth about $218,000. Sigma Planning Corp bought a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth about $225,000. Finally, GSA Capital Partners LLP bought a new position in shares of Centessa Pharmaceuticals during the third quarter worth about $455,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $39.75 on Monday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $10.95 and a 12 month high of $40.26. The stock has a 50 day moving average of $36.56 and a 200-day moving average of $29.39. The company has a market capitalization of $5.93 billion, a P/E ratio of -22.21 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,112 shares of company stock valued at $8,424,535 over the last quarter. 4.09% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of analyst reports. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $40.70.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.